Equillium Inc at SRAX Sequire Biotechnology Conference (Virtual) Transcript
Good afternoon. My name is Bruce Steel, I am the Co-Founder and Chief Executive Officer of Equillium. Very pleased to present to you today the Equillium's story and describe our mission to improve the lives of patients suffering from diseases of unmet -- high unmet need. We do have forward-looking statements to be aware of that you can reference here in our securities filings.
Equillium is a company that was started to dramatically impact the lives of patients suffering from a variety of autoimmune and inflammatory disorders of severe unmet medical need. We are developing first-in-class therapeutics across a range of therapeutic modalities. These are all novel programs.
We have two drugs in development currently that are multi-cytokine targeted therapies. We also have another drug in development called itolizumab that is an antibody targeting CD6. That program was recently partnered with Ono Pharmaceuticals, one of Japan's leading pharmaceutical companies. And we'll tell you a bit more about that partnership in a moment.
We
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |